news
Soil’s hidden bacteria could hold future antibiotic breakthroughs
Researchers have unlocked the genetic secrets of soil’s hidden bacteria, discovering hundreds of previously unknown genomes and two promising new antibiotics.
List view / Grid view
Drug Discovery Processes
article
Advancing antiviral therapeutics for immunocompromised populations
With few antiviral options available to immunocompromised patients, a new generation of therapies - like AIC468 - is aiming to change that.
news
Tumour stress drives T cell exhaustion – antioxidants may reverse it
A new research study has discovered that targeted antioxidants could restore T cell function – offering a potential boost for cancer immunotherapies like CAR-T.
news
Single-cell technique tracks boron in live tumour cells
Researchers at the University of Birmingham have developed a single-cell technique to track boron inside live tumour cells – making Boron Neutron Capture Therapy more effective in treating head and neck cancers.
article
Making sense of AI: bias, trust and transparency in pharma R&D
AI is increasingly used in drug discovery, but hidden bias and ‘black box’ models threaten trust and transparency. This article explores how explainable AI can turn opaque predictions into clear, accountable insights.
news
Scientists spotlight lung disease as fast-track model for ageing drugs
Researchers have identified idiopathic pulmonary fibrosis (IPF) as a powerful model for exploring treatments that target the biology of ageing.
webinar
Pain Research: WRPRFa as a Novel Tool for Acid-Sensing Ion Channel 3 (ASIC3)
3 September 2025 | By Eurofins DiscoverX
Join this webinar to learn how WRPRFa, a novel peptide tool selective for ASIC3, advances pain research and supports drug discovery in peripheral nociceptors.
news
Three powerful antibodies discovered with potential to treat mpox
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
article
Inside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
news
Feline cancer breakthrough could help treat human tumours
Researchers have tested a new cancer drug in pet cats with head and neck squamous cell carcinoma – a disease notoriously hard to treat. The trial showed the therapy controlled cancer in 35 percent of cats with minimal side effects – and it could help to treat humans too.
article
Beyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
news
New M13 virus method could change future genetic treatments
Researchers at the University of Waterloo have developed a modified bacterial virus that can deliver gene therapies cheaper and more efficiently – moving us closer toward personalised, affordable genetic medicine.
news
New imaging technique tracks obesity drug tirzepatide in cells
Scientists have developed fluorescent probes that reveal how dual agonist drugs like tirzepatide target cells in the pancreas and brain, offering new insights into diabetes and obesity treatments.
article
Inside the Alzheimer’s study backing stem cells, not drugs
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
news
Chikungunya’s 2025 surge sparks urgent research response
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
